2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP02.10

EP02.10 - Bingfei Xu

Pdf Summary

The study investigates the efficacy of combining Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) with bevacizumab in treating patients with non-small cell lung cancer (NSCLC) who have become resistant to EGFR-TKI therapy, including those with acquired or primary resistance. Drug resistance is a known challenge in EGFR-TKI treatments, so approaches that delay disease progression are important.<br /><br />The research demonstrates that patients previously resistant to EGFR-TKI treatments benefit from the addition of bevacizumab, regardless of whether their resistance was acquired or primary. The study included 75 patients who were rechallenged with the EGFR-TKI plus bevacizumab regimen after showing resistance to initial EGFR-TKI treatments. Among these, 67 patients had EGFR mutations.<br /><br />Key findings include that baseline EGFR mutation status (such as T790M, 19del, L858R, or uncommon mutations) did not significantly alter the efficacy of the combination therapy. Additionally, while brain metastasis influenced therapy outcomes, this effect was not statistically significant.<br /><br />The study concludes that EGFR-TKI rechallenge with bevacizumab effectively prolongs the time to treatment failure (TTF) in NSCLC patients who have progressed on EGFR-TKIs. This combination could be a promising new strategic treatment for patients with both acquired and primary resistance to EGFR-TKIs. It also highlights the need for further exploration of potential biomarkers that could help predict which patients might benefit most from this therapy. The study was supported by the Guangdong Association of Clinical Trials and other institutions, and data was collected from January 2016 to December 2020.<br /><br />Overall, the combination of EGFR-TKIs and bevacizumab offers a durable therapeutic option in cases of TKI resistance, although ongoing research is needed to optimize patient selection and treatment outcomes.

Keywords

EGFR-TKI

bevacizumab

non-small cell lung cancer

NSCLC

drug resistance

EGFR mutation

T790M

treatment failure

biomarkers

brain metastasis